

Emicizumab

Adjudication Guideline

Rule Category:
Pharmaceutical

Ref: No:
2023-PH-0034

Version Control:
Version No.2

Effective Date:
28/01/2024

Revision Date:
08/11/2024

Approved by:
Daman

Responsible:
Pharmacy Standards &
Governance

**Related Adjudication
Guidelines:** N/A

Table of Contents

1. Abstract	3
1.1 For Members	3
1.2 For Medical Professionals	3
2. Scope	3
3. Adjudication Policy	4
3.1 Eligibility / Coverage Criteria	4
3.2 Requirements for Coverage	5
3.3 Non-Coverage	6
3.4 Payment and Coding Rules	6
4. Denial codes	6
5. Appendices	6
5.1 References	6
5.2 Revision History	7

1. Abstract

1.1 For Members

Emicizumab is a medication that gives to patients with hemophilia A with or without factor VIII inhibitors, which is a condition where blood doesn't clot as it should. It's like a substitute clotting factor, stepping in to prevent and manage bleeding episodes. Its typically prescribed and administered by eligible clinician specialties. These professionals have the expertise to assess the individual needs of patients with haemophilia and determine the appropriate use and dose of Emicizumab based on factors like the type and severity of haemophilia.

1.2 For Medical Professionals

Haemophilia A is a rare condition that affects the blood's ability to clot. Haemophilia A is usually inherited and usually occurs in males. Instances of haemophilia in females are rare.

Symptoms of haemophilia A can be mild to severe, depending on the patient's level of clotting factor VIII. People with haemophilia A may bruise easily and bleed for longer than people who do not have haemophilia A.

People with haemophilia A are currently treated by replacing the missing factor VIII.

Emicizumab is indicated for routine **prophylaxis** of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency):

- With factor VIII inhibitors.
- Without factor VIII inhibitors who have:
 - i. severe disease (FVIII < 1%).
 - ii. moderate disease (FVIII \geq 1% and \leq 5%) with severe bleeding phenotype.

Emicizumab can be used in all patient age.

2. Scope

This guideline provides information on the coverage criteria for Emicizumab, a medication used for the prevention or reduction of bleeding episodes in patients with haemophilia A with or without factor VIII inhibitors. It is designed to ensure appropriate use and allocation of resources for this therapy.

DOSAGE AND ADMINISTRATION

Table A.

Level	Dosage	Interval
Initiation or loading dose	3 mg/kg	Once weekly for first 4 weeks
Maintenance dose	1.5mg/kg	Once weekly or every 2 weeks or every 4 weeks.

Dosage forms and Name/Strengths of the medicinal products available:

Table B.

Generic Name	Dosage form
Emicizumab	30 mg/mL in a single-dose vial
Emicizumab	60 mg/0.4 mL in a single-dose vial
Emicizumab	105 mg/0.7 mL in a single-dose vial
Emicizumab	150 mg/mL in a single-dose vial

Discontinue prophylactic use of bypassing medications the day before starting Emicizumab. The prophylactic use of Factor VIII products may be continued during the first week of Emicizumab prophylaxis.

- If appropriate, a patient or caregiver may self-inject Emicizumab.
- Self-administration is not recommended for children < 7 years of age.

3. Adjudication Policy

3.1 Eligibility / Coverage Criteria

- Patient must have a confirmed diagnosis of haemophilia A with or without factor VIII inhibitors.
- Documentation of clinical symptoms, family history, factor VIII activity level
- Inhibitor levels and history of inhibitor development should be evaluated.
- Documentation of previous treatment(s) with factor VIII replacement therapy and evidence of suboptimal response or adverse effects should be provided

Table C. Initial therapy for patients:

Condition	Description
Haemophilia A with Factor VIII Inhibitors	Positive Factor VIII inhibitor titre if it is greater than 5 Bethesda Units OR
	Positive Factor VIII inhibitor titre less than or equal to 5 Bethesda Units AND Patient experienced an inadequate clinical response of Factor VIII product treatment dosing.
Haemophilia A without Factor VIII Inhibitors	Severe to moderate severe disease as defined by pre-treatment Factor VIII levels $\leq 2\%$ of normal: OR
	Factor VIII levels <u>greater than 2% of normal</u> AND has one of the following: <ul style="list-style-type: none"> A. Patient has experienced a severe, traumatic, or spontaneous bleeding episode. B. Patient has haemophilia-related joint damage, has experienced a joint bleed, or has a specific joint that is subject to recurrent bleeding (presence of a target joint). C. Patient is in a perioperative situation and/or has an additional clinical scenario regarding bleeding/bleeding risk in which the prescriber determines the use of Emicizumab is warranted.

- Investigations prior to initiation, dosing, and re-initiation:

Table D.

Test	Reference range
Chromogenic FVIII activity tests	Decreased or absent factor VIII levels: Severe: <0.01 international units/mL Moderate: 0.01 to 0.05 international units/mL Mild: >0.05 but <0.40 international units/mL
Anti-Emicizumab antibodies once yearly	

3.2 Requirements for Coverage

- Failure to submit, upon request or when requesting a clinical history, indication the need for testing will result in rejection of claim.
- Kindly code the ICD-10 and the CPT codes to the highest level of specificity.
- Covered only for eligible clinician specialties.

Eligible clinician speciality
Internal Medicine
Hematology
Pediatric Oncology and Hematology
Medical Oncology
Critical Care Medicine

3.3 Non-Coverage

- Visitor plan

3.4 Payment and Coding Rules

- DOH payment rules and regulations and relevant coding manuals for ICD, Drugs.

4. Denial Codes

Regulator denial codes with description are elaborated for reference. These are specialized codes directed by regulator, that explains the reason of rejection of the service by DAMAN to the providers.

Code	Code Description
CODE-010	Activity/diagnosis inconsistent with clinician specialty
MNEC-004	Service is not clinically indicated based on good clinical practice
MNEC-003	Diagnoses are not covered
AUTH-001	Prior approval is required and was not obtained

5. Appendices

5.1 References

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf
<https://www.hemlibra.com/content/dam/gene/hemlibra/pdfs/patient/startinghemlibra-brochure.pdf>
<https://www.medicines.org.uk/emc/product/9042/smhc#gref>
<https://haemophilia.ie/new-treatment-option-for-prophylaxis-in-severe-haemophilia-a/>
https://www.hemophilia.org/sites/default/files/document/files/268_Emicizumab.pdf
<https://www.england.nhs.uk/wp-content/uploads/2019/08/1819-Emicizumab->

[asprophylaxis-in-people-with-severe-congenital-haemophilia-A-without-factor-VIIIinhibitors.pdf https://pubmed.ncbi.nlm.nih.gov/34418287/](https://pubmed.ncbi.nlm.nih.gov/34418287/)

5.2 Revision History

Date	Version No.	Change(s)
28/01/2024	V1.0	New version
08/11/2024	V2.0	No changes/ updated in the new format

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed. Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.